Cancer Genetics hopes to raise $6 million in an initial public offering. The Rutherford, N.J.-based company will use part of the proceeds to finance its joint initiative with the Mayo Foundation for Medical Education and Research to use advanced sequencing technology to develop cancer diagnostic tests and services.
N.J. cancer Dx firm looks to obtain $6M from IPO
SmartBrief Job Listings for Health Care
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
|Director of Clinical Research||
Regenesis Biomedical, Inc.
Meridian Health Plan
|Assistant Vice President - Dental Director||